improving anti-pd-1/pd-l1 therapy for localized bladder cancer
Published 3 years ago • 100 plays • Length 3:27Download video MP4
Download video MP3
Similar videos
-
2:41
should pd-l1 be used as a biomarker for immunotherapy in bladder cancer?
-
1:21
how can we improve responses to immunotherapy in patients with bladder cancer?
-
1:09
dragon: srk-181 alone/in combination with anti-pd-l1 treatment in patients with advanced solid tumor
-
2:26
pd-l1 immunotherapy in bladder cancer
-
1:24
anti–pd-1/pd-l1 therapy of human cancer
-
3:36
anti-pd-l1 immunotherapy with mpdl3280a in metastatic bladder cancer
-
2:52
pd-l1 and tmb as biomarkers in the imvigor211 trial of atezolizumab vs. chemo for bladder cancer
-
2:49
nsclc: the increasing need for pd-l1 testing
-
1:32
utility of pd-l1 as a biomarker in bladder cancer
-
1:33
dr. luciano rossetti on the function of anti-pd-l1 treatments in bladder cancer
-
3:26
bladder cancer study for cisplatin-ineligible patients after progression on pd-1 or pd-l1 therapy
-
1:12
dr. sharma on pd-l1 as biomarker for immunotherapy in bladder cancer
-
2:50
the evolution of pd-l1 immunotherapy for bladder cancer
-
7:55
pd-l1 expression in bladder cancer
-
1:16
explaining immunotherapy, pd-l1 and pd-1
-
7:06
pd-l1 in metastatic bladder cancer - bladder cancer video library
-
2:12
cancer immunotherapy | the pd-l1 pathway
-
7:37
combining immunotherapies: inhibiting the ctla-4 and pd-1 pathways
-
0:46
immune checkpoint inhibitors: recent progress and potential biomarkers - 3iv pd-l1 overexpression